p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
复制标题

DOI:
--
复制
发表时间:
1998-05
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
通讯作者:
H. Lenz;K. Danenberg;C. Leichman;B. Florentine;P. Johnston;S. Groshen;Linyun Zhou;Y. Xiong;P. Danenberg;L. Leichman
H. Lenz;K. Danenberg;C. Leichman;B. Florentine;P. Johnston;S. Groshen;Linyun Zhou;Y. Xiong;P. Danenberg;L. Leichman
中科院分区:
其他
文献类型:
--
作者:
H. Lenz;K. Danenberg;C. Leichman;B. Florentine;P. Johnston;S. Groshen;Linyun Zhou;Y. Xiong;P. Danenberg;L. Leichman

文献摘要

相似文献

我们发起了一项回顾性研究,以确定原发性结肠癌肿瘤中p53状态和胸腺苷酸合成酶(TS)蛋白表达是否影响II期结肠癌患者的复发和生存。采用免疫组化方法对45例连续未治疗的II期结肠癌患者的肿瘤标本进行p53和TS蛋白表达检测。中位随访时间为5.1年。18例为左侧肿瘤,27例为右侧肿瘤。45例患者中有14例(31%)复发。18例(40%)肿瘤中检测到P53过表达;10例(55%)p53过表达患者复发;无p53过表达证据的27例患者中有4例(15%)复发(P = 0.002)。TS高表达16例(36%),高表达8例(50%)复发,低表达6例(21%)复发(P = 0.027)。p53过表达患者的生存率明显低于无p53过表达患者(P < 0.001)。TS高表达与生存率低相关(P = 0.004)。p53过表达和TS高表达与左侧肿瘤有显著相关性(P = 0.003和P = 0.022)。16例TS高表达患者中有13例(81%)也过表达p53, 29例TS低表达患者中有24例(81%)未出现p53过表达(P < 0.001)。p53和TS在原发性II期结肠癌中的表达是相关的,并且似乎影响复发和生存。在本初步研究中,左侧肿瘤的p53过表达明显高于右侧肿瘤,TS表达明显高于右侧肿瘤,这可能解释了左侧肿瘤患者生存率明显较低的原因。
We initiated a retrospective study to determine whether p53 status and thymidylate synthase (TS) protein expression in primary colon tumors influence recurrence and survival for patients with stage II colon cancer. Tumor specimens from 45 consecutive untreated patients with stage II colon cancer were examined for p53 and TS protein expression using immunohistochemistry. The median follow-up was 5.1 years. Eighteen patients had left-sided tumors, and 27 had right-sided tumors. Fourteen of 45 patients (31%) developed recurrence. p53 overexpression was detected in the tumors of 18 patients (40%); 10 patients (55%) with p53 overexpression recurred; and 4 of 27 (15%) without evidence of p53 overexpression recurred (P = 0.002). High TS expression was detected in the tumors of 16 patients (36%): 8 patients (50%) with high TS expression recurred, and 6 patients (21%) with low TS expression recurred (P = 0.027). Patients with p53 overexpression had a significantly poorer survival than did those patients without p53 overexpression (P < 0.001). High TS expression was associated with poor survival (P = 0.004). p53 overexpression and high TS expression were significantly associated with left-sided tumors (P = 0.003 and P = 0.022). Thirteen of 16 patients (81%) with high TS expression also overexpressed p53, and 24 of 29 patients (81%) with low TS expression did not manifest p53 overexpression (P < 0.001). p53 and TS expression in primary stage II colon cancer are associated and appear to influence recurrence and survival. In this pilot study, left-sided tumors demonstrate significantly more p53 overexpression and significantly higher TS expression than do right-sided tumors, which may explain the significantly poorer survival for patients with left-sided tumors.